Maternal care for anti-D [Rh] antibodies, third trimester (fetus 1)
ICD-10 O36.0131 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, third trimester (fetus 1).
O36.0131 refers to maternal care for a pregnancy complicated by the presence of anti-D (Rh) antibodies during the third trimester for the first fetus. This condition arises when an Rh-negative mother carries an Rh-positive fetus, leading to the potential for hemolytic disease of the newborn (HDN). The presence of these antibodies can cause fetal complications such as growth restriction, fetal distress, and even fetal demise if not monitored and managed appropriately. Maternal care involves regular monitoring of the fetus through ultrasound assessments, Doppler studies to evaluate blood flow, and possibly intrauterine transfusions if severe anemia is detected. The management plan may also include administering Rh immunoglobulin (RhoGAM) to prevent further sensitization in future pregnancies. Close collaboration between obstetricians and maternal-fetal medicine specialists is essential to ensure optimal outcomes for both mother and fetus.
Detailed records of maternal blood type, antibody screening results, and fetal monitoring outcomes.
Management of pregnancies with known Rh incompatibility, monitoring for signs of fetal distress or growth restriction.
Ensure accurate coding of any interventions performed, such as amniocentesis or intrauterine transfusions.
Comprehensive documentation of high-risk assessments, including ultrasound findings and Doppler studies.
Complex cases involving multiple fetal assessments and interventions due to Rh sensitization.
Focus on the multidisciplinary approach to care, including consultations and referrals.
Used for comprehensive obstetric care in a patient with anti-D antibodies.
Document all visits, assessments, and interventions related to the pregnancy.
Ensure that all aspects of care are captured, especially any referrals to specialists.
Coding O36.0131 is crucial for identifying pregnancies at risk due to Rh incompatibility, allowing for appropriate monitoring and intervention to prevent fetal complications.
